See more : Ever Reach Group (Holdings) Company Limited (3616.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Golden Throat Holdings Group Company Limited (6896.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Golden Throat Holdings Group Company Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- IQ-AI Limited (IQAI.L) Income Statement Analysis – Financial Results
- ACSL Ltd. (AOMUF) Income Statement Analysis – Financial Results
- Gungnir Resources Inc. (ASWRF) Income Statement Analysis – Financial Results
- SL Green Realty Corp. (SLG-PI) Income Statement Analysis – Financial Results
- KT Skylife Co., Ltd. (053210.KS) Income Statement Analysis – Financial Results
Golden Throat Holdings Group Company Limited (6896.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.goldenthroat.com
About Golden Throat Holdings Group Company Limited
Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine to relive symptoms of sore and dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat lozenge series products that include Dule lozenges and sugar-free Dule lozenges in various flavors, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn; Yinxingye tablet, which is designed to facilitate blood circulation, remove blood stasis, and dredge energy channels; and herbal vegetable beverages for soothing voice and relieving sore throats. The company also exports its products to the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 961.38M | 992.01M | 820.54M | 646.94M | 797.13M | 694.19M | 624.08M | 768.17M | 706.92M | 606.80M | 548.86M |
| Cost of Revenue | 263.66M | 271.09M | 242.81M | 171.30M | 198.67M | 177.68M | 188.50M | 213.23M | 184.82M | 176.89M | 181.99M |
| Gross Profit | 697.72M | 720.92M | 577.74M | 475.64M | 598.46M | 516.52M | 435.59M | 554.94M | 522.10M | 429.91M | 366.86M |
| Gross Profit Ratio | 72.57% | 72.67% | 70.41% | 73.52% | 75.08% | 74.40% | 69.80% | 72.24% | 73.86% | 70.85% | 66.84% |
| Research & Development | 0.00 | 6.42M | 22.29M | 2.79M | 2.89M | 2.20M | 2.09M | 1.72M | 2.29M | 2.78M | 2.92M |
| General & Administrative | 94.58M | 78.56M | 103.18M | 83.53M | 77.24M | 65.88M | 56.23M | 69.19M | 78.36M | 59.10M | 47.11M |
| Selling & Marketing | 266.40M | 278.82M | 261.09M | 253.19M | 308.45M | 290.03M | 305.55M | 319.03M | 255.38M | 213.29M | 230.11M |
| SG&A | 360.98M | 357.60M | 364.79M | 336.84M | 385.99M | 355.90M | 361.77M | 388.22M | 333.74M | 272.39M | 277.78M |
| Other Expenses | 0.00 | -1.69M | -630.00K | -2.53M | -9.55M | -29.85M | -1.88M | -14.43M | -3.06M | -5.30M | 0.00 |
| Operating Expenses | 348.23M | 353.38M | 349.67M | 291.98M | 381.18M | 371.57M | 340.70M | 375.78M | 319.41M | 261.05M | 272.17M |
| Cost & Expenses | 614.63M | 624.47M | 592.48M | 463.28M | 579.85M | 549.25M | 529.19M | 589.01M | 504.22M | 437.95M | 454.17M |
| Interest Income | 24.13M | 8.45M | 8.78M | 6.23M | 2.64M | 4.51M | 692.00K | 3.86M | 276.00K | 12.02M | 2.45M |
| Interest Expense | 10.70M | 10.29M | 7.98M | 11.50M | 9.81M | 5.17M | 4.77M | 7.27M | 10.09M | 13.54M | 0.00 |
| Depreciation & Amortization | 39.03M | 38.64M | 36.98M | 31.92M | 9.51M | 6.32M | 6.22M | 5.48M | 5.22M | 8.52M | 8.47M |
| EBITDA | 410.75M | 424.93M | 281.80M | 233.31M | 218.16M | 160.95M | 79.42M | 168.88M | 190.47M | 178.89M | 90.82M |
| EBITDA Ratio | 42.73% | 40.12% | 29.99% | 25.81% | 27.37% | 23.90% | 12.73% | 21.99% | 26.94% | 26.90% | 16.55% |
| Operating Income | 336.74M | 363.32M | 212.95M | 138.81M | 212.47M | 160.61M | 73.20M | 163.40M | 185.25M | 154.73M | 82.35M |
| Operating Income Ratio | 35.03% | 36.62% | 25.95% | 21.46% | 26.65% | 23.14% | 11.73% | 21.27% | 26.21% | 25.50% | 15.00% |
| Total Other Income/Expenses | 24.28M | 12.67M | 23.90M | 51.08M | -5.93M | -11.16M | 9.65M | -4.74M | -1.61M | -16.77M | 9.90M |
| Income Before Tax | 361.02M | 375.99M | 236.85M | 189.89M | 219.92M | 149.45M | 94.20M | 175.30M | 202.42M | 156.84M | 92.24M |
| Income Before Tax Ratio | 37.55% | 37.90% | 28.86% | 29.35% | 27.59% | 21.53% | 15.09% | 22.82% | 28.63% | 25.85% | 16.81% |
| Income Tax Expense | 110.86M | 94.78M | 49.20M | 35.83M | 52.31M | 47.27M | 32.82M | 72.39M | 47.81M | 35.13M | 22.33M |
| Net Income | 250.16M | 281.22M | 187.64M | 154.05M | 167.61M | 102.19M | 61.38M | 102.91M | 154.62M | 121.89M | 69.92M |
| Net Income Ratio | 26.02% | 28.35% | 22.87% | 23.81% | 21.03% | 14.72% | 9.84% | 13.40% | 21.87% | 20.09% | 12.74% |
| EPS | 0.34 | 0.38 | 0.25 | 0.21 | 0.23 | 0.14 | 0.08 | 0.14 | 0.24 | 0.22 | 0.00 |
| EPS Diluted | 0.34 | 0.38 | 0.25 | 0.21 | 0.23 | 0.14 | 0.08 | 0.14 | 0.24 | 0.22 | 0.00 |
| Weighted Avg Shares Out | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 747.51M | 638.66M | 544.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 739.30M | 747.51M | 638.66M | 544.77M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports